ResearchHub | Open Science Community

Justin Doan

Author with expertise in Cancer Immunotherapy

Achievements

Cited Author

Open Access Advocate

Key Stats

Upvotes received:

Publications:

(75% Open Access)

Cited by:

4,511

h-index:

i10-index:

Reputation

Biology

< 1%

Chemistry

< 1%

Economics

< 1%

How is this calculated?

Publications

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert Motzer et al.Mar 21, 2018

Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.

Paper

Save

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

David Cella et al.Jan 16, 2019

Paper

Save

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025

Bernard Escudier et al.Apr 12, 2017

Paper

Save

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

David Cella et al.Jun 6, 2016

Paper

Save